A systematic analysis of FDA-approved anticancer drugs

BackgroundThe discovery of novel anticancer drugs is critical for the pharmaceutical research and development, and patient treatment. Repurposing existing drugs that may have unanticipated effects as potential candidates is one way to meet this important goal. Systematic investigation of efficient anticancer drugs could provide valuable insights into trends in the discovery of anticancer drugs, which may contribute to the systematic discovery of new anticancer drugs.ResultsIn this study, we collected and analyzed 150 anticancer drugs approved by the US Food and Drug Administration (FDA). Based on drug mechanism of action, these agents are divided into two groups: 61 cytotoxic-based drugs and 89 target-based drugs. We found that in the recent years, the proportion of targeted agents tended to be increasing, and the targeted drugs tended to be delivered as signal drugs. For 89 target-based drugs, we collected 102 effect-mediating drug targets in the human genome and found that most targets located on the plasma membrane and most of them belonged to the enzyme, especially tyrosine kinase. From above 150 drugs, we built a drug-cancer network, which contained 183 nodes (150 drugs and 33 cancer types) and 248 drug-cancer associations. The network indicated that the cytotoxic drugs tended to be used to treat more cancer types than targeted drugs. From 89 targeted drugs, we built a cancer-drug-target network, which contained 214 nodes (23 cancer types, 89 drugs, and 102 targets) and 313 edges (118 drug-cancer associations and 195 drug-target associations). Starting from the network, we discovered 133 novel drug-cancer associations among 52 drugs and 16 cancer types by applying the common target-based approach. Most novel drug-cancer associations (116, 87%) are supported by at least one clinical trial study.ConclusionsIn this study, we provided a comprehensive data source, including anticancer drugs and their targets and performed a detailed analysis in term of historical tendency and networks. Its application to identify novel drug-cancer associations demonstrated that the data collected in this study is promising to serve as a fundamental for anticancer drug repurposing and development.

[1]  和泉 堯己,et al.  CLL(Chronic lymphocytic leukemia)〔和文〕 , 2000 .

[2]  M. Blagosklonny,et al.  Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy , 2004, Cell cycle.

[3]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[4]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[5]  Jeffrey W. Clark,et al.  Targeted Agents: The Rules of Combination , 2007, Clinical Cancer Research.

[6]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[7]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[8]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[9]  James H. Doroshow,et al.  Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements , 2010, Nature Reviews Drug Discovery.

[10]  L. Rajendran,et al.  Subcellular targeting strategies for drug design and delivery , 2010, Nature Reviews Drug Discovery.

[11]  Son Doan,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..

[12]  D. K. Arrell,et al.  Network Systems Biology for Drug Discovery , 2010, Clinical pharmacology and therapeutics.

[13]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[14]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[15]  William Pao,et al.  Translating genomic information into clinical medicine: Lung cancer as a paradigm , 2012, Genome research.

[16]  P. Workman,et al.  Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.

[17]  B. Baldo,et al.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch , 2013, Cancer and Metastasis Reviews.

[18]  Sahdeo Prasad,et al.  Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.

[19]  S. Elledge,et al.  Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.

[20]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[21]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Biao He,et al.  Chinese a Nti鄄 Cancer a Ssociation , 2022 .

[23]  Paul S Mischel,et al.  A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. , 2013, Carcinogenesis.

[24]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[25]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[26]  Ester Lovsin Barle,et al.  Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics. , 2014, Regulatory toxicology and pharmacology : RTP.

[27]  M. Kinch,et al.  An analysis of FDA-approved drugs for oncology. , 2014, Drug discovery today.

[28]  Khader Shameer,et al.  In silico methods for drug repurposing and pharmacology , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.

[29]  T. Efferth,et al.  Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. , 2016, Pharmacological research.